Sopra Steria - 2019 Universal registration document

5 2019 CONSOLIDATED FINANCIAL STATEMENTS Notes to the consolidated financial statements

At 31 December 2019, accumulated translation reserves by currency were as follows:

31/12/2019

31/12/2018

(in millions of euros)

Swiss franc

7.9

6.2

Pound sterling Indian rupee Norwegian krone

-49.6

-80.5

2.6

5.1

-18.0

-19.2

Polish zloty

-0.2

-0.3

Singapore dollar Tunisian dinar

0.5

0.2

-1.7

-2.5

US dollar

-

3.4 3.7

Other currencies

1.3

ACCUMULATED TRANSLATION RESERVES (ATTRIBUTABLE TO THE GROUP)

-57.2

-83.9

The “Other currencies” category mainly includes the accumulated translation reserves of associates, and chiefly Axway Software, in the amount of €8.3 million (€7.4 million at 31 December 2018). Non-controlling interests 14.1.5. The contributions to the income statement and balance sheet of entities in which there are non-controlling interests mainly come from joint ventures formed with the UK authorities in the United Kingdom region: NHS SBS, 50%-owned by the UK Department of Health, and SSCL, 25%-owned by the Cabinet Office. The Group has 50% and 75% control, respectively. They also relate to the companies in the Galitt group acquired in 2017, as well as companies in the SAB group and Sopra Financial Technology GmbH acquired in 2019.

The Group has granted the Cabinet Office a put option to sell the shares it holds in SSCL. In the same vein, the Group has entered into an irrevocable commitment to acquire the remaining shares in Galitt and in SAB, in the form of a put option granted to the other shareholders. Due to the accounting treatment of the put option granted in respect of SSCL, Galitt and SAB shares, the amount of non-controlling interests on the balance sheet mainly relates to the UK Department of Health’s share in the net assets of NHS SBS (€32.8 million), and the share of the German banking network Sparda’s cooperative banks in Sopra Financial Technology GmbH (€17.7 million). In the income statement, amounts attributable to non-controlling interests mainly comprised €7.0 million for SSCL and €3.1 million for NHS SBS.

Summary financial information for SSCL, NHS SBS, Galitt, SAB and Sopra Financial Technology GmbH is as follows:

31/12/2019

SSCL

NHS SBS

Galitt

SAB 94.1 18.7 11.9 21.0 37.1

SFT

(in millions of euros)

Non-current assets

14.4

33.7 70.4 19.7 18.7 92.6

42.9

108.9

Current assets

153.5

9.6 7.8

10.3 52.6 25.0 86.3

Non-current liabilities

19.5 60.6

Current liabilities

-11.1 34.6

Revenue

204.5 28.1

NET PROFIT

6.2

2.4

3.5

2.5

Non-controlling interests arise where a portion of equity ownership in a subsidiary is not attributable directly or indirectly to the parent company. When non-controlling interests have an option to sell their investment to the Group, a financial liability is recorded in Other non-current liabilities (see Note 7.4) for the present value of the option’s estimated exercise price. The offset of the financial liability generated by these commitments is deducted from:

the corresponding amount of non-controlling interests initially; p and the Group’s share of consolidated reserves for the remainder. p Subsequent changes in this put option arising from changes in estimates or relating to the unwinding of discount are offset against the corresponding non-controlling interests and the remainder is deducted from the Group’s share of consolidated reserves.

211

SOPRA STERIA UNIVERSAL REGISTRATION DOCUMENT 2019

Made with FlippingBook - Online catalogs